CF
SGMO

Centaurus Financial’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Centaurus Financial’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,350
Closed -$19K – 1782
2018
Q2 		$19K Buy
+1,350
New +$22.4K ﹤0.01% 1308

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Centaurus Financial's SGMO Position: Q3 2018 in Review

Centaurus Financial sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2018, closing a stake of 1,350 shares — an estimated $19K sold.

Centaurus Financial first reported a position in SGMO in Q2 2018 and held it in 1 quarter. The position peaked at $19K in Q2 2018. 217 funds tracked by Wall St. Rank hold SGMO as of Q3 2018.

  • Centaurus Financial reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2018 after selling out during the quarter.
  • Centaurus Financial sold 1,350 SANGAMO THERAPEUTICS INC shares in Q3 2018, an estimated $19K.
  • Centaurus Financial first reported a position in SANGAMO THERAPEUTICS INC in Q2 2018 and held it in 1 quarter.
  • Centaurus Financial's SANGAMO THERAPEUTICS INC position peaked at $19K in Q2 2018.
  • 217 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.